Adeona Pharmaceuticals Profit Margin
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AEN Profit Margin Range, Past 5 Years
| Minimum | -31770.00% | Jun 2002 |
| Maximum | -1.20% | Mar 2000 |
| Average |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these AEN related companies
AEN News
Adeona (AEN) Appoints Chairman Jeff Riley as CEO; Names Two Board Members
Feb 06, 6:31AM Street Insider
Feb 06, 6:31AM Street Insider
Great chart,most likely a P&D,though Timesta &or Flupirtine data could be out soon.Watch 4 dilutions $AEN http://chart.ly/2dbior4
about 35 days ago by Wiserguy1971
about 35 days ago by Wiserguy1971
$AEN http://stks.co/1orA Chart for @wiserguy1971 , very bullish, fib targets on chart, 2.02 next target
about 36 days ago by Tr8r_x
about 36 days ago by Tr8r_x
$aen out 1.55 took 10 cents. not gonna hold this overnight. most likely it a pos
about 38 days ago by kunal00
about 38 days ago by kunal00
$aen http://stks.co/1mlJ big breakout here. in here 1.45 daytrade only.
about 38 days ago by kunal00
about 38 days ago by kunal00
$AEN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1mLX
about 38 days ago by MarketBrief
about 38 days ago by MarketBrief
Adeona Pharmaceuticals (AEN) Announces Possible Name Change, Appoints John Monahan Senior VP of R&D
Dec 21, 7:04AM Street Insider
Dec 21, 7:04AM Street Insider
Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator
Nov 30, 6:41AM Benzinga
Nov 30, 6:41AM Benzinga
Adeona (AEN) Reports Encouraging Data from Zinc Therapy Phase I/II in ALS
Nov 30, 6:32AM Street Insider
Nov 30, 6:32AM Street Insider
Adeona, Intrexon in worldwide exclusive collaboration for synthetic DNA therapy
Nov 21, 6:31AM FlyOnTheWall
Nov 21, 6:31AM FlyOnTheWall
Adeona, Skirball Foundation to jointly advance multiple sclerosis research
Nov 11, 9:07AM FlyOnTheWall
Nov 11, 9:07AM FlyOnTheWall
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Nov 11, 9:00AM PR Newswire
Nov 11, 9:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AEN | 2.71 | 0.02 | 0.74% | 76.10M |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| OLP | 17.76 | -0.48 | -2.63% | 257.34M |
| ANR | 21.04 | -1.36 | -6.07% | 4.76B |
| BFLY | 2.13 | -0.00 | -0.12% | 52.36M |
| TMK | 47.20 | 0.53 | 1.14% | 4.81B |
| AMPL | 0.39 | 0.00 | 0.13% | 21.91M |
| AU | 45.11 | -0.82 | -1.79% | 17.21B |
| EONC | 1.66 | 0.15 | 9.93% | 4.75M |
| GFI | 16.47 | -0.20 | -1.20% | 11.93B |
